Nationwide Commercial Laboratory Seroprevalence Survey

Metadata Updated: December 14, 2020

CDC is working with commercial laboratories to conduct large-scale geographic seroprevalence surveys to estimate the percentage of people who were previously infected with SARS-CoV-2, the virus that causes COVID-19 disease. The strategy involves working with state, local, territorial, academic, and commercial partners to better understand COVID-19 in the United States using serology (antibody) testing for surveillance (“seroprevalence surveys” or “serosurveys”). For the surveys, de-identified clinical blood samples are tested for antibodies to SARS-CoV-2. This dataset contains the data used to by the Nationwide Commercial Laboratory Seroprevalence Survey interactive visualization available at Additional information is available at

Access & Use Information

Public: This dataset is intended for public access and use. License: No license information was provided. If this work was prepared by an officer or employee of the United States government as part of that person's official duties it is considered a U.S. Government Work.

Downloads & Resources


Metadata Created Date November 10, 2020
Metadata Updated Date December 14, 2020

Metadata Source

Harvested from

Additional Metadata

Resource Type Dataset
Metadata Created Date November 10, 2020
Metadata Updated Date December 14, 2020
Publisher Centers for Disease Control and Prevention
Unique Identifier Unknown
Data First Published 2020-10-22
Data Last Modified 2020-12-10
Category Laboratory Surveillance
Public Access Level public
Bureau Code 009:20
Metadata Context
Metadata Catalog ID
Schema Version
Catalog Describedby
Homepage URL
Program Code 009:020
Source Datajson Identifier True
Source Hash 6b8750171a950023302db71991f4d96d3f94dfa9
Source Schema Version 1.1

Didn't find what you're looking for? Suggest a dataset here.